Adenoviral Mediated Interferon-α 2b Gene Therapy Suppresses the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Superficial Bladder Cancer

Journal of Urology

Volumn 177, Issue 5, 2007, Pages 1900-1906

  Adam, Liana ^a   Black, Peter C ^a   Kassouf, Wassim ^a   Eve, Beryl ^a   McConkey, David ^a   Munsell, Mark F ^a   Benedict, William F ^a   Dinney, Colin P N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoviridae; angiogenesis inhibitors; bladder; bladder neoplasms; interferons

Indexed keywords

ADENOVIRUS VECTOR; ALPHA2B INTERFERON; BEVACIZUMAB; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C MYB; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERFICIAL CANCER; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2B; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-MYB; RNA, NEOPLASM; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR AP-2; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34147147630     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.003     Document Type: Article

References (19)

1. Garmendia G., Miranda N., Borroso S., Longchong M., Martinez E., Ferrero J., et al. Regression of infancy hemangiomas with recombinant IFN-alpha 2b. J Interferon Cytokine Res 21 (2001) 31
2. Albini A., Marchisone C., Del Grosso F., Benelli R., Masiello L., Tacchetti C., et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 156 (2000) 1381
3. Dinney C.P., Bielenberg D.R., Perrotte P., Reich R., Eve B.Y., Bucana C.D., et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58 (1998) 808
4. Slaton J.W., Perrotte P., Inoue K., Dinney C.P., and Fidler I.J. Interferon-alpha-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 272
5. Glashan R.W. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144 (1990) 658
6. Benedict W.F., Tao Z., Kim C.S., Zhang X., Zhou J.H., Adam L., et al. Intravesical Ad-IFN-alpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 10 (2004) 525
7. Izawa J.I., Sweeney P., Perrotte P., Kedar D., Dong Z., Slaton J.W., et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8 (2002) 1258
8. Yang C.C., Chu K.C., and Yeh W.M. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22 (2004) 1
9. von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95 (2003) 420
10. Kassouf W., Dinney C.P., Brown G., McConkey D.J., Diehl A.J., Bar-Eli M., et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 65 (2005) 10524
11. Papageorgiou A., Lashinger L., Millikan R., Grossman H.B., Benedict W., Dinney C.P., et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 64 (2004) 8973
12. O'Donnell M.A., Lilli K., and Leopold C. National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. J Urol 172 (2004) 888
13. Kuznetsov D.D., Alsikafi N.F., O'Connor R.C., and Steinberg G.D. Intravesical valrubicin in the treatment of carcinoma in situ of bladder. Expert Opin Pharmacother 2 (2001) 1009
14. Kim J.C., and Steinberg G.D. Medical management of patients with refractory carcinoma in situ of the bladder. Drugs Aging 18 (2001) 335
15. Bein K., Ware J.A., and Simons M. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J Biol Chem 273 (1998) 21423
16. Clark-Lewis I., Mattioli I., Gong J.H., and Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278 (2003) 289
17. Luster A.D., Unkeless J.C., and Ravetch J.V. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315 (1985) 672
18. Yamada H., Luo Y., Matsumoto T., and O'Donnell M.A. A novel expression of macrophage derived chemokine in human bladder cancer. J Urol 173 (2005) 990
19. Poppas D.P., Pavlovich C.P., Folkman J., Voest E.E., Chen X., Luster A.D., et al. Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52 (1998) 268